Advertisement

Annals of Hematology

, Volume 62, Issue 6, pp 221–224 | Cite as

A study of the myeloid differentiation antigens of the peripheral blood neutrophil granulocytes in the different evolutive phases of chronic myeloid leukemia

  • M. Rozman
  • F. Cervantes
  • C. Rozman
Original Article

Summary

To ascertain whether progression from the chronic to the accelerated and blastic phases of chronic myeloid leukemia (CML) is associated with the loss of the myeloid differentiation antigens of the neutrophil granulocytes (NG), we analyzed two monoclonal antibodies (PMN 31D8 and PMN 13F6) recognizing normal peripheral blood NG membrane antigens in 49 patients in different evolutive stages of CML. Since five patients were studied twice, a total of 54 studies were carried out. Fourteen patients were evaluated at diagnosis, 12 in the controlled chronic phase within 1 year from diagnosis, 14 in the advanced chronic phase (median evolution 3.25 years), and 14 in the accelerated (five cases) or blastic (nine cases) phases. Fourteen normal subjects served as a control group. At diagnosis, a significant decrease in the positivity for both antigens was observed with respect to controls, probably due to the circulation of incompletely mature NG. In the early chronic phase the values were within the normal range, whereas a significant decrease was registered in the advanced chronic phase and especially in the accelerated/blastic phase. A negative correlation between the NG positivity for both markers and the time elapsed from the moment of obtaining the initial control of the disease was found, suggesting that a progressive loss of the myeloid antigens of the NG occurs during the evolutive course of CML. These results seem to confirm the usefulness of the NG myeloid differentiation antigen study as an evolutive parameter in CML.

Key words

Chronic myeloid leukemia Neutrophil granulocytes Prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Armitage P (1971) Statistical methods in medical research. Blackwell Scientific Publications, OxfordGoogle Scholar
  2. 2.
    Cervantes F, Rozman C (1982) A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 60: 1298–1304Google Scholar
  3. 3.
    Cordell JL, Falini B, Erber WN et al. (1984) Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase, and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219–229Google Scholar
  4. 4.
    Dixon WJ, Brown MB, Engelman L, Hill MA, Jennrich RI (1988) BMDP Statistical Software Manual, University of California Press, BerkeleyGoogle Scholar
  5. 5.
    Gallin JI, Jacobson RJ, Seligmann B, Metcalf JA, McKay JH, Sacher RA, Malech HL (1986) A neutrophil marker reveals two groups of chronic myelogenous leukemia and its absence may be a marker of disease progression. Blood 68: 343–346Google Scholar
  6. 6.
    Goldman JM, Baughan ASJ (1984) Chronic granulocytic leukemia: treatment. In: Goldman JM, Preisler HD (eds) Leukemias. Butterworth International Medical Reviews, vol 8. Butterworths, London, pp 239–265Google Scholar
  7. 7.
    Goldman JM, Gale RP, Horowitz MM et al. (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 108: 806–814Google Scholar
  8. 8.
    Kantarjian HM, Smith TL, McCredie KB et al. (1968) Clinical implications of cytogenetic variants in chronic myelocytic leukemia. Blood 32: 755–766Google Scholar
  9. 9.
    Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ (1988) Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61: 1441–1446Google Scholar
  10. 10.
    Koeffler HP, Golde DW (1981) Chronic myelogenous leukemia — new concepts. N Engl J Med 304: 1201–1209Google Scholar
  11. 11.
    Mills KI, McKenzie ED, Birnie GD (1988) The site of breakpoint within thebcr is a prognostic factor in Philadelphiapositive CML patients. Blood 72: 1237–1241Google Scholar
  12. 12.
    Pedersen B (1982) Functional and biochemical phenotype in relation to cellular age of differentiated neutrophils in chronic myeloid leukaemia. Br J Haematol 12: 633–645Google Scholar
  13. 13.
    Sokal JE, Cox EB, Baccarani M et al. (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63: 789–799Google Scholar
  14. 14.
    Spiers ASD (1979) Metamorphosis of chronic granulocytic leukaemia: diagnosis, classification and management. Br J Haematol 41: 1–7Google Scholar
  15. 15.
    Thomas E, Clift RA, Fefer A et al. (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163Google Scholar
  16. 16.
    Todd MB, Wadrom JA, Jennings TA et al. (1987) Loss of myeloid differentiation antigens precedes blastic transformation in chronic myelogenous leukemia. Blood 70: 122–131Google Scholar
  17. 17.
    Tura S, Baccarani M, Corbelli G, Italian Cooperative Study Group on Chronic Myeloid Leukaemia (1981) Staging of chronic myeloid leukaemia. Br J Haematol 37: 105–119Google Scholar
  18. 18.
    Wareham NJ, Johnson SA, Goldman JM (1982) Relationship of the duration of chronic phase in chronic granulocytic leukemia to the need for treatment during the first year after diagnosis. Cancer Chemother Pharmacol 8: 205–210Google Scholar
  19. 19.
    Whang-Peng J, Canellos GP, Carbone PP, Tjio JH (1968) Clinical implications of cytogenetic variants in chronic myelocytic leukemia. Blood 32: 755–766Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • M. Rozman
    • 1
  • F. Cervantes
    • 1
  • C. Rozman
    • 1
  1. 1.Postgraduate School of Hematology “Farreras Valentí”, Hospital ClinicUniversity of BarcelonaSpain

Personalised recommendations